Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor In their article, Kitley and colleagues1 characterized the features of patients with neuromyelitis optica (NMO)/NMO spectrum disorders (NMOSDs) with myelin-oligodendrocyte glycoprotein antibodies (Abs) and compared them with patients with aquaporin-4 antibody (AQP4-Ab)–positive NMO/NMOSD. They found that patients with myelin-oligodendrocyte glycoprotein Abs who fulfilled the diagnostic criteria for NMO were different from those with AQP4-Abs in terms of sex preponderance, age distribution, and involvement of conus and deep gray matter structures on imaging, as well as outcomes.1
Gao J, Pan W, Zhang H. Features of Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies. JAMA Neurol. 2014;71(7):923-924. doi:10.1001/jamaneurol.2014.764